ArticleJournal for immunotherapy of cancer2022

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.

Valerie Glutsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.